Business
Hemostemix Announces the Appointment of David Tsubouchi to its Board of Advisors
Calgary, Alberta--(Newsfile Corp. - April 30, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF)...
About this update from Hemostemix Inc
[{"type":"text","content":"Hemostemix Announces the Appointment of David Tsubouchi to its Board of AdvisorsCalgary, Alberta--(Newsfile Corp. - April 30, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (\"Hemostemix\" or the \"Company\") is pleased to announce the appointment of David H. Tsubouchi, B.A., J.D., LL.D., D.S.Litt., C.Dir. to its Board of Advisors.David Tsubouchi is the first Japanese Canadian to be elected to any provincial legislature in Canada and to be appointed as a Cabinet Minister. He has served as the Minister of Consumer and Commercial Relations, Solicitor General, Chair of Management Board and Minister of Culture. Mr. Tsubouchi sits on the boards of OMERS Pension Fund, Lakefront Utilities and the Ontario Arts Council. He has previously served as the Honourary Consul General of Mongolia. As the former Registrar and CEO of the Ontario College of Trades he oversaw the regulation of the skilled trades in Ontario. He has also served as the Integrity Commissioner for the Town of Richmond Hill. His book, Gambatte was nominated for the Speaker's Book Award and the Heritage Toronto Book Award. \"Our team is delighted to be working closely with and taking counsel from David Tsubouchi, as his breadth of experience and relationships of trust span our legal, political, business and finance sectors,\" said Thomas Smeenk, President & CEO. \"I am looking forward to working with Thomas Smeenk and advising the team at Hemostemix,\" said David Tsubouchi. \"Healthcare is and will continue to be a priority of not only Canada but of the world. An entrepreneurial Canadian stem cell company that has global aspirations and a public good purpose to improve the quality of life of many will be inspirational and exciting to work with,\" Mr. Tsubouchi said. ABOUT HEMOSTEMIX Hemostemix is a publicly traded autologous stem cell therapy company. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat over 300 patients, and it is the subject of a randomized, placebo-controlled, double blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputatio...